REG - AstraZeneca PLC - Director/PDMR Shareholding <Origin Href="QuoteRef">AZN.L</Origin>

AstraZenecaAnnouncement

15/12/2017 12:00

RNS Number : 4980Z
AstraZeneca PLC
15 December 2017
15 December 2017 12:00 GMT
TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES
Disclosure under Article 19 of the EU Market Abuse Regulation
AstraZeneca PLC (the Company) announces that, on 14 December 2017, it was notified by Pascal Soriot, a Director of the Company, that, on 13 December 2017, Mr Soriot ceased to be beneficially interested in 40,148 Ordinary Shares of $0.25 each in the Company, following the gift of those shares to family members for nil consideration.
The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.
1 
Details of the person discharging managerial responsibilities / person closely associated 
a) 
Name 
Pascal Soriot
2 
Reason for the notification 
a) 
Position/status 
Chief Executive Officer
b) 
Initial notification /Amendment 
Initial notification
3 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a) 
Name 
AstraZeneca PLC
b) 
LEI 
PY6ZZQWO2IZFZC3IOL08
4 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a) 
Description of the financial instrument, type of instrument 
Identification code 
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
b) 
Nature of the transaction 
Gift of shares to family members for nil consideration
c) 
Price(s) and volume(s) 
Price(s)
Volume(s)
0
40,148
d) 
Aggregated information 
- Aggregated volume 
- Price 
Not applicable - single transaction
e) 
Date of the transaction 
13 December 2017
f) 
Place of the transaction 
Outside a trading venue
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. 
For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca. 
Media Relations


Esra Erkal-Paler
UK/Global
+44 203 749 5638
Karen Birmingham
UK/Global
+44 203 749 5634
Rob Skelding
UK/Global
+44 203 749 5821
Matt Kent
UK/Global
+44 203 749 5906
Gonzalo Via
UK/Global
+44 203 749 5916
Jacob Lund
Sweden
+46 8553260 20
Michele Meixell
US
+1 302 885 2677



Investor Relations


Thomas Kudsk Larsen
+44 203 749 5712
Craig Marks
Finance, Fixed Income, M&A
+44 7881 615 764
Henry Wheeler
Oncology
+44 203 749 5797
Mitchell Chan
Oncology; Other
+1 240 477 3771
Christer Gruvris
Brilinta; Diabetes
+44 203 749 5711
Nick Stone
Respiratory; Renal
+44 203 749 5716
US toll free

+1 866 381 7277
Adrian Kemp
Company Secretary
AstraZeneca PLC

This information is provided by RNS
The company news service from the London Stock Exchange
  END
DSHUVVKRBKAUARA